TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model Studies

Cancer is a therapeutically challenging and genomically complicated disease. Pioneering studies have uncovered multifaceted aspects of cancer, ranging from intra- and inter-tumor heterogeneity, drug resistance, and genetic/epigenetic mutations. Loss of apoptosis is another critical aspect that makes...

Full description

Saved in:
Bibliographic Details
Main Authors: Ammad Ahmad Farooqi, Assiya Turgambayeva, Gulnara Kamalbekova, Roza Suleimenova, Natalya Latypova, Sholpan Ospanova, Dinara Ospanova, Zhanat Abdikadyr, Sabit Zhussupov
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/60/12/1977
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850240949063516160
author Ammad Ahmad Farooqi
Assiya Turgambayeva
Gulnara Kamalbekova
Roza Suleimenova
Natalya Latypova
Sholpan Ospanova
Dinara Ospanova
Zhanat Abdikadyr
Sabit Zhussupov
author_facet Ammad Ahmad Farooqi
Assiya Turgambayeva
Gulnara Kamalbekova
Roza Suleimenova
Natalya Latypova
Sholpan Ospanova
Dinara Ospanova
Zhanat Abdikadyr
Sabit Zhussupov
author_sort Ammad Ahmad Farooqi
collection DOAJ
description Cancer is a therapeutically challenging and genomically complicated disease. Pioneering studies have uncovered multifaceted aspects of cancer, ranging from intra- and inter-tumor heterogeneity, drug resistance, and genetic/epigenetic mutations. Loss of apoptosis is another critical aspect that makes cancer cells resistant to death. A substantial fraction of mechanistic information gleaned from cutting-edge studies has enabled researchers to develop near-to-complete resolution of the apoptotic pathway. Within the exciting frontiers of apoptosis, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) has garnered phenomenal appreciation by interdisciplinary researchers principally because of its unique capability to target cancer cells. TRAIL-based monotherapies and combinatorial therapies have reached phase II and phase III clinical trials. Rapidly upgrading the list of clinical trials substantiates the clinically valuable role of TRAIL-based therapeutics in cancer therapy. However, there is a growing concern about the poor bioavailability and rapid clearance of TRAIL-based therapeutics. Excitingly, the charismatic field of nanotechnology offers solutions for different problems, and we have witnessed remarkable breakthroughs in the efficacy of TRAIL-based therapeutics using nanotechnological approaches. In this review, we have attempted to provide a summary about different nanotechnologically assisted delivery methods for TRAIL-based therapeutics in cell culture studies and animal model studies for the inhibition/prevention of cancer.
format Article
id doaj-art-a6f83cc49f5e45ef8a664fa55659e727
institution OA Journals
issn 1010-660X
1648-9144
language English
publishDate 2024-12-01
publisher MDPI AG
record_format Article
series Medicina
spelling doaj-art-a6f83cc49f5e45ef8a664fa55659e7272025-08-20T02:00:43ZengMDPI AGMedicina1010-660X1648-91442024-12-016012197710.3390/medicina60121977TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model StudiesAmmad Ahmad Farooqi0Assiya Turgambayeva1Gulnara Kamalbekova2Roza Suleimenova3Natalya Latypova4Sholpan Ospanova5Dinara Ospanova6Zhanat Abdikadyr7Sabit Zhussupov8Department of Molecular Oncology, Institute of Biomedical and Genetic Engineering (IBGE), Islamabad 44090, PakistanDepartment of Public Health and Management, Astana Medical University, Astana 010000, KazakhstanDepartment of Family Medicine, Astana Medical University, Astana 010000, KazakhstanDepartment of Public Health and Hygiene, Astana Medical University, Astana 010000, KazakhstanDepartment of Family Medicine, Astana Medical University, Astana 010000, KazakhstanDepartment of Public Health and Management, Astana Medical University, Astana 010000, KazakhstanFaculty of Medicine and Healthcare, Al-Farabi Kazakh National University, 71 Al-Farabi Ave, Almaty 050040, KazakhstanDepartment of Biostatistics, Bioinformatics and Information Technologies, Astana Medical University, Astana 010000, KazakhstanDepartment of Surgery, Semey Medical University, Semey 071400, KazakhstanCancer is a therapeutically challenging and genomically complicated disease. Pioneering studies have uncovered multifaceted aspects of cancer, ranging from intra- and inter-tumor heterogeneity, drug resistance, and genetic/epigenetic mutations. Loss of apoptosis is another critical aspect that makes cancer cells resistant to death. A substantial fraction of mechanistic information gleaned from cutting-edge studies has enabled researchers to develop near-to-complete resolution of the apoptotic pathway. Within the exciting frontiers of apoptosis, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) has garnered phenomenal appreciation by interdisciplinary researchers principally because of its unique capability to target cancer cells. TRAIL-based monotherapies and combinatorial therapies have reached phase II and phase III clinical trials. Rapidly upgrading the list of clinical trials substantiates the clinically valuable role of TRAIL-based therapeutics in cancer therapy. However, there is a growing concern about the poor bioavailability and rapid clearance of TRAIL-based therapeutics. Excitingly, the charismatic field of nanotechnology offers solutions for different problems, and we have witnessed remarkable breakthroughs in the efficacy of TRAIL-based therapeutics using nanotechnological approaches. In this review, we have attempted to provide a summary about different nanotechnologically assisted delivery methods for TRAIL-based therapeutics in cell culture studies and animal model studies for the inhibition/prevention of cancer.https://www.mdpi.com/1648-9144/60/12/1977TRAILapoptosiscell signalingmetastasisxenografted micenanotechnology
spellingShingle Ammad Ahmad Farooqi
Assiya Turgambayeva
Gulnara Kamalbekova
Roza Suleimenova
Natalya Latypova
Sholpan Ospanova
Dinara Ospanova
Zhanat Abdikadyr
Sabit Zhussupov
TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model Studies
Medicina
TRAIL
apoptosis
cell signaling
metastasis
xenografted mice
nanotechnology
title TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model Studies
title_full TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model Studies
title_fullStr TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model Studies
title_full_unstemmed TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model Studies
title_short TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model Studies
title_sort trail as a warrior in nano sized trojan horse anticancer and anti metastatic effects of nano formulations of trail in cell culture and animal model studies
topic TRAIL
apoptosis
cell signaling
metastasis
xenografted mice
nanotechnology
url https://www.mdpi.com/1648-9144/60/12/1977
work_keys_str_mv AT ammadahmadfarooqi trailasawarriorinnanosizedtrojanhorseanticancerandantimetastaticeffectsofnanoformulationsoftrailincellcultureandanimalmodelstudies
AT assiyaturgambayeva trailasawarriorinnanosizedtrojanhorseanticancerandantimetastaticeffectsofnanoformulationsoftrailincellcultureandanimalmodelstudies
AT gulnarakamalbekova trailasawarriorinnanosizedtrojanhorseanticancerandantimetastaticeffectsofnanoformulationsoftrailincellcultureandanimalmodelstudies
AT rozasuleimenova trailasawarriorinnanosizedtrojanhorseanticancerandantimetastaticeffectsofnanoformulationsoftrailincellcultureandanimalmodelstudies
AT natalyalatypova trailasawarriorinnanosizedtrojanhorseanticancerandantimetastaticeffectsofnanoformulationsoftrailincellcultureandanimalmodelstudies
AT sholpanospanova trailasawarriorinnanosizedtrojanhorseanticancerandantimetastaticeffectsofnanoformulationsoftrailincellcultureandanimalmodelstudies
AT dinaraospanova trailasawarriorinnanosizedtrojanhorseanticancerandantimetastaticeffectsofnanoformulationsoftrailincellcultureandanimalmodelstudies
AT zhanatabdikadyr trailasawarriorinnanosizedtrojanhorseanticancerandantimetastaticeffectsofnanoformulationsoftrailincellcultureandanimalmodelstudies
AT sabitzhussupov trailasawarriorinnanosizedtrojanhorseanticancerandantimetastaticeffectsofnanoformulationsoftrailincellcultureandanimalmodelstudies